ALK and non-small cell lung carcinoma: ,11 Non-smoking NSCLC patients in particular show an enrichment in EML4-ALK and limited mutation of the epidermal growth factor receptor (EGFR), which restricts the efficacy of traditional EGFR-targeted therapeutics such as gefitinib and erlotinib.12